Biotech News
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
ir.macrogenics.com2026-05-06 14:58 EST
Newly-appointed President and CEO, Eric Risser , outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ ® Cash, cash equivalents and marketable securities of $176.5 million as of June 30,